Results 111 to 120 of about 13,113,839 (405)

Proteo-genomic analyses in relatively lean Chinese adults identify proteins and pathways that affect general and central adiposity levels

Communications Biology
Adiposity is an established risk factor for multiple diseases, but the causal relationships of different adiposity types with circulating protein biomarkers have not been systematically investigated.
Andri Iona, Pang Yao, Alfred Pozarickij, Christiana Kartsonaki, Saredo Said, Neil Wright, Kuang Lin, Iona Millwood, Hannah Fry, Mohsen Mazidi, Baihan Wang, Yiping Chen, Huaidong Du, Ling Yang, Daniel Avery, Dan Schmidt, Dianjianyi Sun, Pei Pei, Jun Lv, Canqing Yu, Michael Hill, Junshi Chen, Fiona Bragg, Derrick Bennett, Robin Walters, Liming Li, Robert Clarke, Zhengming Chen, China Kadoorie Biobank Collaborative Group   +28 more
doaj   +1 more source

A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects

Clinical and Translational Science, 2023
This study aimed to evaluate the pharmacokinetic (PK) similarity of the proposed biosimilar HS628 compared with the reference tocilizumab (Actemra®) and also to demonstrate similar safety and immunogenicity profiles in healthy Chinese male subjects ...
Hongjie Qian, Jie Cheng, Yuzhou Gui, Wei Wang, Liyu Liang, Huijuan Zhu, Qingqing Wu, Meixian Ou, Qian Chen, Chen Yu, Jingying Jia   +10 more
doaj   +1 more source

Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct [PDF]

, 2013
Background In 2010, after regulatory review of rosiglitazone licensing, the US Food and Drug Administration (FDA) requested a reevaluation of cardiovascular end points in the RECORD trial.<p></p> Methods Automated screening of the ...
Bigelow, Robert, Burns, Shana, Dickerson, Sheila, Hafley, Gail, Home, Philip D., Komajda, Michel, Lopes, Renato D., Mahaffey, Kenneth W., McMurray, John, Newby, L. Kristin, Tourt-Uhlig, Sandra, White, Jennifer   +11 more
core   +2 more sources

Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation

JAMA Oncology, 2019
Importance The American Society of Clinical Oncology (ASCO), Friends of Cancer Research, and the US Food and Drug Administration recently recommended modernizing criteria related to comorbidities routinely used to exclude patients from cancer clinical ...
J. Unger, D. Hershman, M. Fleury, R. Vaidya   +3 more
semanticscholar   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source

Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial

Trials
Introduction ASCEND PLUS is a randomised controlled trial assessing the effects of oral semaglutide on the primary prevention of cardiovascular events in around 20,000 individuals with type 2 diabetes in the UK.
Muram El-Nayir, Rohan Wijesurendra, David Preiss, Marion Mafham, Leandros Tsiotos, Sadman Islam, Anne Whitehouse, Sophia Wilkinson, Hannah Freeman, Ryonfa Lee, Wojciech Brudlo, Genna Bobby, Bryony Jenkins, Robert Humphrey, Amy Mallorie, Andrew Toal, Elnora C. Barker, Dianna Moylan, Graeme Thomson, Firoza Davies, Hameed Khan, Ian Allotey, Susan Dickie, John Roberts   +23 more
doaj   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

Blood Cancer Journal, 2018
Substantial improvements in survival have been seen in multiple myeloma (MM) over recent years, associated with the introduction and widespread use of multiple novel agents and regimens, as well as the emerging treatment paradigm of continuous or long ...
P. Richardson, J. S. San Miguel, P. Moreau, R. Hájek, M. Dimopoulos, J. Laubach, A. Palumbo, K. Luptakova, D. Romanus, T. Skácel, Shaji K. Kumar, K. Anderson   +11 more
semanticscholar   +1 more source

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

Molecular Oncology, EarlyView.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke, Marie Tölle, Philipp Walter, Kira Meißner, Mara Goetz, Jolanthe Kropidlowski, Andreas W. Berger, Jakob R. Izbicki, Felix Nickel, Thilo Hackert, Klaus Pantel, Harriet Wikman, Faik G. Uzunoglu   +12 more
wiley   +1 more source

Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism

Frontiers in Pharmacology
IntroductionSuraxavir Marboxil (GP681) is a prodrug metabolized to GP1707D07, which inhibits influenza viral replication by targeting cap-dependent endonuclease through a single oral dose.
Mai Han, Gang Cui, Yan Zhao, Xianbo Zuo, Xiaoxue Wang, Xin Zhang, Na Mi, Jiangli Jin, Chunyan Xiao, Jing Wang, Wei Wu, Yajuan Li, Jintong Li   +12 more
doaj   +1 more source